QTRX

Quanterix Corp

QTRX, USA

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

https://www.quanterix.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
QTRX
stock
QTRX

What drives QTRX stock price - Technical Resistance Breaks & Get Peace of Mind with Portfolio Health Checks earlytimes.in

Read more →
QTRX
stock
QTRX

Aug Catalysts: Why analysts upgrade QTRX stock - July 2025 Pullbacks & Real-Time Market Sentiment Reports moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6

Analyst Picks

Strong Buy

1

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.11

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-10.66 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.55 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-104.42 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.41

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 84.96% of the total shares of Quanterix Corp

1.

Ameriprise Financial Inc

(9.1182%)

since

2025/06/30

2.

Portolan Capital Management, LLC

(7.82%)

since

2025/06/30

3.

BlackRock Inc

(6.2943%)

since

2025/06/30

4.

Vanguard Group Inc

(5.4426%)

since

2025/06/30

5.

Kent Lake PR LLC

(4.952%)

since

2025/06/30

6.

CT (Lux) American Smaller Com 9U USD

(4.0781%)

since

2025/07/31

7.

Strategic Advisers U.S. Total Stock

(4.0722%)

since

2025/07/31

8.

Vanguard Total Stock Mkt Idx Inv

(2.6921%)

since

2025/07/31

9.

CT American Smaller Coms(US) InstAccGBP

(2.6453%)

since

2025/07/31

10.

Invenomic Capital Management, LP

(2.464%)

since

2025/06/30

11.

William Blair Investment Management, LLC

(2.4275%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(2.1758%)

since

2025/08/31

13.

Blue Water Life Science Advisors, LLC

(2.0612%)

since

2025/06/30

14.

Geode Capital Management, LLC

(1.9091%)

since

2025/06/30

15.

Dimensional Fund Advisors, Inc.

(1.7297%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(1.6602%)

since

2025/06/30

17.

Balyasny Asset Management LLC

(1.6524%)

since

2025/06/30

18.

State Street Corp

(1.6461%)

since

2025/06/30

19.

Williams Jones Wealth Management, LLC

(1.4549%)

since

2025/06/30

20.

Baillie Gifford & Co Limited.

(1.293%)

since

2025/06/30

21.

Trium Capital LLP

(1.2621%)

since

2025/06/30

22.

Tikvah Management LLC

(1.2302%)

since

2025/06/30

23.

Columbia Small Cap Value Discv A

(1.2236%)

since

2025/07/31

24.

Columbia Small Cap Value Discovery Fund

(1.2044%)

since

2025/06/30

25.

Parkman Healthcare Partners LLC

(1.1105%)

since

2025/06/30

26.

abrdn Life Sciences Investors

(0.9974%)

since

2025/08/31

27.

Invenomic Institutional

(0.9787%)

since

2025/04/30

28.

Easterly Murphy Large Cap Value

(0.9602%)

since

2025/07/31

29.

Marshall Wace Asset Management Ltd

(0.956%)

since

2025/06/30

30.

Acadian Asset Management LLC

(0.9139%)

since

2025/06/30

31.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9091%)

since

2025/07/31

32.

Baillie Gifford Global Discovery A Acc

(0.8418%)

since

2025/07/31

33.

William Blair Small Cap Growth I

(0.8319%)

since

2025/07/31

34.

Fidelity Small Cap Index

(0.7959%)

since

2025/06/30

35.

iShares Russell 2000 Value ETF

(0.6876%)

since

2025/08/31

36.

Columbia Trust US Smaller Companies Fund

(0.5721%)

since

2025/06/30

37.

iShares Biotechnology ETF

(0.5064%)

since

2025/08/31

38.

Portolan Select

(0.4748%)

since

2024/12/31

39.

Fidelity Extended Market Index

(0.4603%)

since

2025/07/31

40.

Edinburgh Worldwide Ord

(0.4512%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.4247

Latest Release

Date

2025-09-30

EPS Actual

-0.73

EPS Estimate

-0.4648

EPS Difference

-0.2652

Surprise Percent

-57.0568%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.